Dabigatran Pradaxa For Stroke Prevention In Patients With Non Valvular Atrial Fibrillation

Dabigatran Pradaxa For Stroke Prevention In Patients With Non Valvular Atrial Fibrillation. See full list on nejm.org The design of this study has been described previously.9

(PDF) Observational study of the effects of dabigatran on ... from www.researchgate.net

See full list on ahajournals.org Atrial fibrillation increases the risks of stroke and death. The mean chads2 score was 2.1 (table 1).

Quinidine use was permitted until 2 years after the trial started, when the protocol was amended to prohibit its use, because of its potential to interact with dabigatran.

The appropriate regulatory authorities and ethics committees approved the study. A large number of patients with af have vhd and therefore are often seen in routine clinical practice. The only adverse effect that was significantly more common with dabigatran than with warfarin was dyspepsia (table 4). See full list on ahajournals.org

The rate of major bleeding was 3.36% per year in the warfarin group, as compared with 2.71% per year in the group that received 110 mg of dabigatran (relative risk with dabigatran, 0.80;

Robinson (core adjudication only), j.

Investigators who recruited at least 12 patients:

See full list on nejm.org

Vitamin k antagonists, such as warfarin, reduce the risks of stroke and death but increase the risk of hemorrhage as compared with control therapy.1 therefore, warfarin is recommended for patients who have atrial fibrillation and are at risk for stroke.2

These data were reported back to the participating centers with advice for optimal inr control.

Cox regression was used to calculate relative risks, confidence intervals, and p values.

A large number of patients with af have vhd and therefore are often seen in routine clinical practice.

Atrial fibrillation increases the risks of stroke and death.

Location:

Share :